Smith Group Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Smith Group Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,160	Closed	-$682K	–	449
2018 Q2	$682K	Buy	5,160 +100	+2%	+$9.43K	0.02%	192
2018 Q1	$375K	Sell	5,060 -4,100	-45%	-$273K	0.01%	206
2017 Q4	$510K	Hold	9,160	–	–	0.02%	211
2017 Q3	$415K	Hold	9,160	–	–	0.01%	228
2017 Q2	$309K	Sell	9,160 -100	-1%	-$3.26K	0.01%	244
2017 Q1	$274K	Hold	9,260	–	–	0.01%	234
2016 Q4	$254K	Buy	+9,260	New	+$372K	0.01%	234

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Smith Group Asset Management's SRPT Position: Q3 2018 in Review

Smith Group Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 5,160 shares — an estimated $682K sold.

Smith Group Asset Management first reported a position in SRPT in Q4 2016 and held it in 7 quarters. The position peaked at $682K in Q2 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

Smith Group Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
Smith Group Asset Management sold 5,160 Sarepta Therapeutics shares in Q3 2018, an estimated $682K.
Smith Group Asset Management first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 7 quarters.
Smith Group Asset Management's Sarepta Therapeutics position peaked at $682K in Q2 2018.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Smith Group Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.